IMMP — —
Loading…
— —
PREV CLOSE — OPEN — DAY RANGE —
Analyzing 0%
MASTER — —
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN Ranks Forecast News Intelligence Fundamentals ESEN Deep Analysis Screener
ESEN NEWS INTELLIGENCE — IMMP
SENTIMENT
POSITIVE
IMPACT LEVEL
HIGH
REPORTING PERIOD
Nov 5–19, 2026
HEADLINE COUNT
5 Material Items
AI SUMMARY

Immutep released encouraging Phase 2 survival data from EFTISARC-NEO trial showing 81.1% 12-month disease-free survival and 94.1% local recurrence-free survival in 38 soft tissue sarcoma patients receiving efti + KEYTRUDA + radiotherapy. The company expanded its U.S. patent portfolio with a key patent for efti-based combination therapies valid through 2038. Additional late-breaking data from ACR Convergence 2026 demonstrated statistically significant, exposure-dependent inhibition of T-cell-driven immune responses with IMP761 in healthy volunteers. These clinical and intellectual property developments support advancement of Immutep's immuno-oncology pipeline.

KEY HEADLINES
Date (UTC) Headline Source
Nov 18, 2026 Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Benzinga
Nov 11, 2026 Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies Yahoo
Nov 10, 2026 EFTISARC-NEO Phase II Sarcoma Survival Data: Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS Benzinga
Nov 7, 2026 IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant T-Cell Inhibition Yahoo
Nov 5, 2026 Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology Congress Yahoo
POSITIVE CLINICAL & IP MOMENTUM — Multiple Phase 2 efficacy readouts, favorable patent expansion, and positive mechanistic data support pipeline advancement. No material adverse disclosures identified in reporting window.

Compliance Note: This summary is for informational purposes only and reflects publicly disclosed material published during the specified reporting window. LIVE_DATA as of 2026-11-19T01:08:48Z. No investment recommendation is expressed or implied. Readers should conduct independent due diligence and consult with qualified advisors.

SNAPSHOT
Ticker
IMMP
Company
Immutep Ltd
Sector / Industry
Biotechnology
Market Cap
$35.4M AUD
Current Price
$3.25 AUD
52W Range
$0.02 – $0.47
52W Return
–91.8%
Exchange
ASX
EARNINGS MOMENTUM

Critical Data Gap: Earnings dates, historical EPS actuals, consensus estimates, and guidance are not disclosed in available data. Latest EPS (trailing) is –$0.0539 AUD, indicating the company is unprofitable.

Metric Value Assessment
Trailing EPS –$0.0539 Loss-making
EPS Growth YoY Not disclosed Coverage constrained
Revenue Growth YoY 24,185% (*)† Extreme anomaly—likely restart or accounting event
Forward P/E Not disclosed N/A (unprofitable)
Guidance Not available No forward outlook disclosed

* The 24,185% revenue growth figure is anomalous and likely reflects a corporate restructuring, significant deal, or data anomaly rather than organic operational momentum. Requires clarification from company disclosures.

Earnings Momentum Score: 2/10 | SEVERE HEADWINDS — Company is loss-making with no disclosed earnings visibility or guidance. The massive revenue growth figure lacks credibility and context. Momentum trend: NEGATIVE.
PROFITABILITY & QUALITY

Data Status: Financial statements (income statement, cash flow) not available in live data.

Metric Value Implication
Gross Margin Not disclosed Visibility limited
Operating Margin Not disclosed Visibility limited
Net Margin Negative (EPS –$0.0539) Unprofitable
ROE / ROIC Not disclosed Likely negative—unsuitable metric for loss-making firm
FCF TTM Not disclosed Visibility limited
Quality Flags Hyper-growth (flagged)
No strong profitability (flagged)
Company is in R&D/pre-revenue or early-stage biotech phase
Quality Score: 1/10 | POOR — Immutep is an unprofitable biotech with no visible margin structure. Operational quality cannot be assessed due to lack of profitability and detailed financials. This is a pre-commercial or clinical-stage asset play, not a traditional earnings business.
BALANCE SHEET HEALTH

Data Status: Balance sheet and cash flow statements not available in live data.

Metric Value Assessment
Cash & Equivalents Not disclosed Critical gap for burn-rate analysis
Total Debt Not disclosed Critical gap
Net Debt / EBITDA Not disclosed Not meaningful (negative EBITDA)
Interest Coverage Not disclosed Not meaningful (unprofitable)
Current Ratio Not disclosed Liquidity unknown
Share Dilution Not disclosed Dilution history unknown
Weak Balance Flag NOT flagged System shows "false," but lack of visibility is concerning for biotech
Balance Sheet Risk: HIGH | WARNING — Without access to cash position, debt levels, and burn rates, balance sheet health cannot be properly evaluated. For an unprofitable biotech, cash runway and financing ability are critical survival metrics. Recommend obtaining latest quarterly balance sheet and cash flow statements.
VALUATION ANALYSIS
Metric Value Interpretation
Trailing P/E Not meaningful (EPS negative) Company loss-making; P/E not applicable
Forward P/E Not disclosed No consensus forward earnings
PEG Ratio Not calculable Requires forward EPS growth—not available
Price / Sales Not calculable (Revenue TTM not disclosed) Market cap $35.4M; Revenue coverage constrained
Price / FCF Not meaningful (FCF not disclosed; likely negative) Unprofitable; free cash flow typically negative in pre-commercial biotech
EV / EBITDA Not meaningful (negative EBITDA) Company loss-making
Sector Context Biotech peer median not disclosed Relative valuation analysis not possible
Market Cap $35.4M AUD (~$23M USD) Micro-cap; illiquid; speculative risk profile
Valuation Status: SPECULATIVE | NOT INVESTABLE ON FUNDAMENTALS — Traditional valuation metrics (P/E, P/S, P/FCF) do not apply to unprofitable, pre-commercial biotech. Stock is priced on clinical pipeline, patent value, and speculative potential, not earnings power. Market cap of $35M reflects early-stage risk profile. Valuation Score: 2/10.
ANALYST TARGETS & SENTIMENT

Data Status: Wall Street analyst coverage and targets not available in live data.

Metric Value Comment
Consensus Rating Not disclosed No analyst consensus available
Price Target (Mean) Not disclosed No data
Price Target (High/Low) Not disclosed No data
Implied Upside Cannot calculate No target available
Analyst Dispersion Unknown Coverage likely sparse for micro-cap ASX stock
Wall Street Sentiment: UNDETERMINED | LOW COVERAGE — As a small-cap Australian biotech (ASX-listed), Immutep likely has minimal Wall Street coverage. No analyst targets or consensus ratings available. Recommend checking ASX-listed research and investor relations for independent equity research.
INSTITUTIONAL & RISK CHECK
Risk Factor Status Severity
Institutional Ownership Not disclosed Unknown
Insider Activity Not disclosed Unknown
Short Interest Not disclosed Unknown
Liquidity Micro-cap; avg volume 8.87M shares HIGH RISK
Volatility (Beta) 2.03 (highly volatile) HIGH RISK
52-Week Price Action –91.8% YTD; down from $0.47 to $3.25 current; 52W low $0.02 SEVERE
Financial Distress Unprofitable; no visibility on cash position CRITICAL
Sector Risk Early-stage biotech; clinical/pipeline risk; regulatory risk HIGH RISK
Risk Level: EXTREME | RED FLAG PROFILE — Immutep is a micro-cap, highly volatile biotech with severe capital constraints (unprofitable, cash position unknown), limited institutional support, extreme 52-week losses (–91.8%), and high beta (2.03). This is a high-risk, speculative, early-stage asset. Suitable only for high-risk venture/biotech specialists with deep due diligence. NOT suitable for conservative or institutional portfolios.
FINAL ESEN VERDICT
28
Overall Fundamental Score: 28/100
Conviction Level: LOW — Insufficient data quality, extreme volatility, unprofitable operations, and undisclosed financials make a high-conviction assessment impossible. Any investment thesis depends entirely on clinical pipeline milestones and capital availability.
TIME HORIZON GRID
SHORT (1–3M)
AVOID
Binary risk; pending catalysts unclear
MEDIUM (6–12M)
SPECULATIVE
Clinical data catalysts; capital raise
LONG (2Y+)
VENTURE
Path to profitability; regulatory approvals
EXECUTIVE SUMMARY
  • Unprofitable Pre-Commercial Biotech: Immutep is a loss-making, early-stage immunotherapy developer with negative EPS (–$0.0539) and no disclosed earnings visibility or guidance. Traditional valuation metrics do not apply.
  • Critical Data Gaps: Financial statements, cash position, debt levels, clinical trial status, and analyst coverage are not available. This severely limits the ability to assess survival probability or clinical value.
  • Extreme Volatility & Micro-Cap Illiquidity: Beta 2.03; 52-week loss of –91.8%; market cap $35.4M. High risk of further dilution or capital distress. Not suitable for conservative investors.
  • Pipeline-Dependent Valuation: Stock price is 100% dependent on clinical milestone announcements, partnerships, or capital raises. No intrinsic earnings power. Requires deep biotech expertise and high risk tolerance.
  • Recommendation: AVOID for institutional portfolios. Only for venture/biotech specialists with dedicated pipeline research and high-risk capital allocation. Obtain latest quarterly financials, cash burn analysis, and clinical trial updates directly from company before any position consideration.
Analysis as of 2026-11-19 | Data sourced from LIVE_DATA (Finnhub) | Coverage constrained due to data gaps | Not investment advice

IMMP Stock AI Analysis

ESEN AI analysis of IMMP stock updated every 12 hours.

AI STOCK INSIGHT

IMMP Stock Analysis & Forecast

Is IMMP a Good Investment in 2026?

Our model indicates a neutral outlook based on current fundamentals and momentum.

IMMP Stock Forecast

Based on recent earnings trends, valuation metrics, and sector performance, IMMP shows balanced risk-reward characteristics.

Should You Buy IMMP Now?

Investors should consider market conditions, volatility, and long-term positioning before taking a position in IMMP.

Related Stocks
AAPL NVDA MSFT AMZN GOOGL META TSLA AVGO JPM V MA LLY UNH XOM JNJ WMT PG HD MRK COST BAC ABBV CRM CVX ORCL KO PEP AMD NFLX ADBE

Explore AI analysis for top stocks — Full Rankings · AI Screener · Earnings Calendar